Identity
- Security key
- 17047
- Ticker
- IMRN
- Type
- ADRC — American Depository Receipt Common
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2007-12-13
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- IMRN
Detail
Enriched 2026-08-14 20:47
- Market cap
- $8,882,357.8
- Shares outstanding (class)
- 8,071,202
- Shares outstanding (weighted)
- 8,071,202
- SIC
- —
- Employees
- 7
- Location
- —
- Homepage
- https://www.immuron.com.au
- Description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.